HUTCHMED (CHINA) LIMIT

HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer

07 8 2022 20:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Initiates Phase I Trial of Anti-CD47 Monoclonal Antibody HMPL-A83 in Patients with Advanced Malignant Neoplasms in China

15 7 2022 04:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Highlights First Presentation of Results of the SAVANNAH Global Phase II Trial of Savolitinib plus TAGRISSO® at the 2022 WCLC Annual Meeting

12 7 2022 20:00:00 提供 Nasdaq GlobeNewswire

Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007

06 7 2022 00:40:34 提供 Nasdaq GlobeNewswire

HUTCHMED to Announce 2022 Half-Year Financial Results

27 6 2022 04:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Announces TAZVERIK® Approved to be Used in Hainan Pilot Zone in China

01 6 2022 04:33:07 提供 Nasdaq GlobeNewswire

Appointment of Non–Executive Director

16 5 2022 07:00:02 提供 Nasdaq GlobeNewswire

HUTCHMED Receives Complete Response Letter from the U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

02 5 2022 06:00:00 提供 Nasdaq GlobeNewswire

Update on Status under Holding Foreign Companies Accountable Act

31 3 2022 00:00:00 提供 Nasdaq GlobeNewswire

Update on Status under Holding Foreign Companies Accountable Act

11 3 2022 04:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Receives a US$15 million Milestone from AstraZeneca for Initiating Start-up Activities for a Global Phase III Study of ORPATHYS® in Lung Cancer

06 3 2022 23:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED announces retirement of CEO and appointment of new CEO

03 3 2022 07:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Reports 2021 Full Year Results and Provides Business Updates

03 3 2022 07:00:01 提供 Nasdaq GlobeNewswire

HUTCHMED Receives Approval to Commercialize ELUNATE® in Macau

01 3 2022 03:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED to Announce 2021 Final Results

07 2 2022 03:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Initiates Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy or Toripalimab for Advanced Solid Tumors in China

04 2 2022 04:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant Solid Tumors and TGCT in China

19 1 2022 19:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Highlights Fruquintinib Clinical Data to be Presented at the 2022 ASCO Gastrointestinal Cancers Symposium

18 1 2022 19:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Receives Breakthrough Therapy Designation in China for HMPL-523 for Treatment of Primary Immune Thrombocytopenia

12 1 2022 06:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously Treated B-Cell Non-Hodgkin Lymphoma in China

09 1 2022 19:00:00 提供 Nasdaq GlobeNewswire